Fig 1: Less ability of Tregs to inhibit the co-stimulation expression on CD1c+ cells in the PBC patients(A) The proportion of Tregs compared with CD1c+ cells with Spearman’s correlation coefficients in the PBC patients (n = 55 and n = 61). (B) Correlation between the proportion of Tregs and CD86 expression on CD1c+ cells in the PBC and HC groups (n = 55 and n = 61). (C) Correlation between the ratio of CD86/Tregs and mayo risk score in the PBC and HC groups (n = 55 and n = 61). (D) CD86 expression on CD1c+ cells when cultured with or without (grey) Tregs from the PBC patients or HCs. (E) Statistical data (n = 8 per group). ANOVAs (E). Data shown are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.01.
Fig 2: Correlation coefficient between each individual values of IGF1R expression and CD1c in EOC patients (P˂.05).
Fig 3: Positive immunohistochemical staining. (A-F) IGFIR, p53, Ki67, BRCA1, CD141, and CD1c in early stage of serous subtypes ovarian carcinoma (×40), respectively. (G-L) IGFIR, p53, Ki67, BRCA1, CD141, and CD1c in advanced stage of serous subtypes ovarian carcinoma (×40), respectively. Scale bar = 50 μm.
Fig 4: Self-antibodies promoted the progression of PBC(A) Comparison of TGF-β levels by PBMCs cultured with IgG in the supernatant. (B-C) The proportion of CD1c+ cells and (D) CD86 expression on CD1c+ cells was detected after PBMCs stimulated with or without (grey) IgG from the HCs and PBC patients by flow cytometry (n = 8 per group). ANOVAs (A), Unpaired Student’s t test (C-D). Data shown are mean ± SD. *P < 0.05, **P < 0.01.
Fig 5: Cell proportion of various gated cell subsets based on Image Cytometry at different disease stage. (A) CD8+ T cells in total CD3+ T cells, (B) CD163+ myelomonocytic cells in total myelomonocytic cells, (C) CD45+ immune cells in total cells, (D) CD1C+ subset in myeloid lineages. Each datapoint represent one ROI. Statistics: Mann-Whitney-Wilcoxon test two-sided with Bonferroni correction: ns (not significant): p > 0.05; *p ≤ 0.05.
Supplier Page from Abcam for Anti-CD1c antibody [OTI2F4]